{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:14:49Z","timestamp":1789676089599,"version":"4.0.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.critrevonc.2026.105346","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T15:08:57Z","timestamp":1777129737000},"page":"105346","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Adjuvant mitotane in low-risk adrenocortical carcinoma: A reconstructed IPD analysis of the ADIUVO randomized and observational studies"],"prefix":"10.1016","volume":"223","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5699-4958","authenticated-orcid":false,"given":"Fabiano","family":"Flauto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Neola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Damiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.critrevonc.2026.105346_bib1","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-25-0034","article-title":"Spanish consensus on the diagnosis and management of adrenocortical carcinoma","volume":"32","author":"Araujo-Castro","year":"2025","journal-title":"Endocr. Relat. Cancer"},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105346_bib2","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1200\/JCO.2009.27.5958","article-title":"Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel","volume":"28","author":"Berruti","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105346_bib3","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1002\/cncr.23886","article-title":"Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors","volume":"113","author":"Bilimoria","year":"2008","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105346_bib4","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3390\/pharmaceutics11110566","article-title":"Population pharmacokinetics modelling and simulation of mitotane in patients with adrenocortical carcinoma: an individualized dose regimen to target all patients at three months?","volume":"11","author":"Cazaubon","year":"2019","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105346_bib5","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1210\/jc.2013-2856","article-title":"Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma","volume":"99","author":"Else","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105346_bib6","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","article-title":"ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Fassnacht","year":"2020","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105346_bib7","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European society of endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur. J. Endocrinol."},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105346_bib8","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"FIRM-ACT Study Group. Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N. Engl. J. Med"},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105346_bib9","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.3390\/cancers16234061","article-title":"A review on mitotane: a target therapy in adrenocortical carcinoma","volume":"16","author":"Flauto","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105346_bib10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1245\/s10434-009-0716-x","article-title":"Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane","volume":"17","author":"Grubbs","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105346_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Method."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105346_bib12","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/bjc.1994.183","article-title":"Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients","volume":"69","author":"Haak","year":"1994","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105346_bib13","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1210\/jc.2010-2676","article-title":"Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study","volume":"96","author":"Hermsen","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105346_bib14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med. Res. Method."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105346_bib15","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1210\/jc.2017-02591","article-title":"German ACC Study Group. Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma","volume":"103","author":"Megerle","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105346_bib16","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3390\/cancers12030740","article-title":"Mitotane concentrations influence outcome in patients with advanced adrenocortical carcinoma","volume":"12","author":"Puglisi","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105346_bib17","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/sim.1203","article-title":"Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects","volume":"21","author":"Royston","year":"2002","journal-title":"Stat. Med"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105346_bib18","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1210\/en.2015-1367","article-title":"Mitotane inhibits Sterol-O-Acyl Transferase 1 triggering lipid-mediated endoplasmic reticulum stress and apoptosis in adrenocortical carcinoma cells","volume":"156","author":"Sbiera","year":"2015","journal-title":"Endocrinology"},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105346_bib19","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1056\/NEJMoa063360","article-title":"Adjuvant mitotane treatment for adrenocortical carcinoma","volume":"356","author":"Terzolo","year":"2007","journal-title":"N. Engl. J. Med"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105346_bib20","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1530\/EJE-13-0242","article-title":"Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection","volume":"169","author":"Terzolo","year":"2013","journal-title":"Eur. J. Endocrinol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105346_bib21","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S2213-8587(23)00193-6","article-title":"Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study","volume":"11","author":"Terzolo","year":"2023","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.critrevonc.2026.105346_bib22","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105346_bib23","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1002\/sim.6556","article-title":"Meta-analysis of time-to-event outcomes from randomized trials using restricted mean survival time: application to individual participant data","volume":"34","author":"Wei","year":"2015","journal-title":"Stat. Med"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826002337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826002337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:05:50Z","timestamp":1780038350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826002337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":23,"alternative-id":["S1040842826002337"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105346","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant mitotane in low-risk adrenocortical carcinoma: A reconstructed IPD analysis of the ADIUVO randomized and observational studies","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105346","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105346"}}